Arcutis Biotherapeutics Inc (ARQT)

Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case - Investing.com Australia

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

Recent Insider Transactions at Arcutis Biotherapeutics - TradingView

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga

Apr 03, 2025

Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com UK

Apr 03, 2025

Apr 03, 2025

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Apr 02, 2025

Apr 02, 2025

Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener

Apr 02, 2025

Apr 02, 2025

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation - Investing.com India

Apr 02, 2025

Apr 02, 2025

Arcutis rises after halting patent dispute with Padagis - TradingView

Apr 02, 2025

Apr 02, 2025

Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times

Apr 02, 2025

Apr 02, 2025

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Apr 02, 2025

Apr 02, 2025

Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine

Apr 02, 2025

Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025

Mar 31, 2025

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN

Mar 31, 2025

Mar 30, 2025

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN

Mar 30, 2025

Mar 28, 2025

Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan

Mar 27, 2025

Mar 27, 2025

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 27, 2025

Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com

Mar 26, 2025

Mar 26, 2025

Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st

Mar 26, 2025

Mar 25, 2025

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Mar 25, 2025

Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zorvye foam - Medical Marketing and Media

Mar 24, 2025

Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - MM+M Online

Mar 24, 2025

Mar 20, 2025

Arcutis Biotherapeutics shares jump - MSN

Mar 20, 2025

Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India

Mar 20, 2025

Mar 17, 2025

What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

Mar 17, 2025

Mar 17, 2025

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow

Mar 17, 2025

Mar 17, 2025

Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail

Mar 17, 2025

Mar 12, 2025

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Mar 12, 2025

Mar 12, 2025

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World

Mar 12, 2025

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World

Mar 12, 2025

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada

Mar 11, 2025

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 10, 2025

Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR

Mar 10, 2025

Mar 10, 2025

Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World

Mar 10, 2025

Mar 09, 2025

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St

Mar 09, 2025